Chiasma Inc (NASDAQ:CHMA) has been given a consensus recommendation of “Buy” by the six analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $10.95.
Several brokerages have recently commented on CHMA. Zacks Investment Research downgraded shares of Chiasma from a “hold” rating to a “sell” rating in a report on Tuesday, April 23rd. Cantor Fitzgerald began coverage on shares of Chiasma in a report on Thursday, March 7th. They issued an “overweight” rating and a $5.84 target price for the company. ValuEngine upgraded shares of Chiasma from a “hold” rating to a “buy” rating in a report on Tuesday, March 5th. Roth Capital began coverage on shares of Chiasma in a report on Tuesday, February 19th. They issued a “buy” rating and a $16.00 target price for the company. Finally, HC Wainwright began coverage on shares of Chiasma in a report on Thursday, February 14th. They issued a “buy” rating and a $11.00 target price for the company.
Shares of CHMA stock traded down $0.01 on Tuesday, hitting $6.06. The stock had a trading volume of 50,784 shares, compared to its average volume of 220,140. The company has a market cap of $148.26 million, a P/E ratio of -4.73 and a beta of 1.49. Chiasma has a 12-month low of $1.20 and a 12-month high of $7.19.
In other news, Director Roni Mamluk sold 10,000 shares of the stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $5.31, for a total value of $53,100.00. Following the completion of the sale, the director now owns 10,000 shares in the company, valued at $53,100. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 6.20% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of CHMA. Vanguard Group Inc increased its holdings in Chiasma by 42.8% during the third quarter. Vanguard Group Inc now owns 324,625 shares of the biotechnology company’s stock worth $1,169,000 after buying an additional 97,272 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Chiasma by 42.8% in the third quarter. Vanguard Group Inc. now owns 324,625 shares of the biotechnology company’s stock worth $1,169,000 after purchasing an additional 97,272 shares in the last quarter. Tibra Equities Europe Ltd purchased a new position in shares of Chiasma in the first quarter worth about $200,000. Dimensional Fund Advisors LP increased its stake in shares of Chiasma by 51.4% in the third quarter. Dimensional Fund Advisors LP now owns 80,986 shares of the biotechnology company’s stock worth $292,000 after purchasing an additional 27,505 shares in the last quarter. Finally, Citadel Advisors LLC increased its stake in shares of Chiasma by 100.6% in the third quarter. Citadel Advisors LLC now owns 35,656 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 17,881 shares in the last quarter. Institutional investors and hedge funds own 64.47% of the company’s stock.
Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
Featured Story: What is a Futures Contract?
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.